| Name | Title | Contact Details |
|---|
TrainOne is a Charlotte, NC-based company in the Business Services sector.
Front Office Sports is the leading multi-platform media and news organization covering the business of sports. Front Office Sports was named one of Fast Companys Most Innovative Companies in 2021, AdWeeks Hottest in Sports in 2022 and 2024, and listed on Inc. 5000 in 2023, recognizing the fastest-growing private companies in America. Interested in working at FOS? All open roles can be found here: https://careers.frontofficesports.com/ Interested in advertising with FOS? All opportunities can be found here: https://advertising.frontofficesports.com/
Meyer Natural Angus, LLC is a Lincoln, NE-based company in the Business Services sector.
About the Agency for Science, Technology and Research (A*STAR) The Agency for Science, Technology and Research (A*STAR) is Singapores lead public sector agency that spearheads economic oriented research to advance scientific discovery and develop innovative technology. Through open innovation, we collaborate with our partners in both the public and private sectors to benefit society. As a Science and Technology Organisation, A*STAR bridges the gap between academia and industry. Our research creates economic growth and jobs for Singapore, and enhances lives by contributing to societal benefits such as improving outcomes in healthcare, urban living, and sustainability. We play a key role in nurturing and developing a diversity of talent and leaders in our Agency and research entities, the wider research community and industry. A*STARs R&D activities span biomedical sciences and physical sciences and engineering, with research entities primarily located in Biopolis and Fusionopolis. For ongoing news, visit www.a-star.edu.sg.
Ensho Therapeutics, Inc. is a privately held, clinical-stage biopharmaceutical company focused on developing breakthrough oral therapies for patients with inflammatory diseases. The companys initial focus is on a pipeline of oral, selective small molecule inhibitors of lymphocyte homing integrin α4β7 for IBD, a mechanism already validated by a commercially available antibody. Enshos assets were acquired from EA Pharma Co., Ltd., a subsidiary of Eisai Co., Ltd., that is focused on gastrointestinal disease. Ensho is preparing to initiate a Phase 2 clinical program in UC with NSHO-101, the lead asset in the companys pipeline.